Sign In
Buy VTRS
$17.56
-0.200 (-1.13%)
At Close: Jul 31, 2026
Viatris: Deep-Value Pharma With Emerging Growth Catalysts And Strong Cash Generation
08:52am, Friday, 20'th Feb 2026
Upcoming launches between 2026–2027, including fast-acting meloxicam, cenerimod, and selatogrel, could support a return to mid-single-digit sales growth and improve margins. With FCF yield above 10%
Earnings Preview: Viatris (VTRS) Q4 Earnings Expected to Decline
11:01am, Thursday, 19'th Feb 2026
Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NESS ZIONA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depo
Dividend Income: Lanny's December 2025 Summary
06:23am, Tuesday, 17'th Feb 2026
In December, we received a dividend income total of $8,010.54. The retirement accounts are composed of HSA investments, ROTH and traditional IRAs, as well as our work 401(k) accounts. In total, divide
PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report fourth quarter and full year 2025 financial results on Thursday, Febr
Viatris Appoints Matthew J. Maletta as Chief Legal Officer
08:30am, Tuesday, 03'rd Feb 2026
Brian Roman to Leave the Company After More Than 20 Years of Exemplary Service; Will Remain Advisor Through Transition Period PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) an
Builds on Viatris' Scientific Leadership and Commercial Legacy in Cardiovascular Diseases PITTSBURGH, Jan. 20, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today anno
Viatris Inc. (VTRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
04:46pm, Tuesday, 13'th Jan 2026
Viatris Inc. (VTRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Burney U.S. Factor Rotation ETF Buys Shares of Viatris Inc (NAS:VTRS)
02:44pm, Tuesday, 13'th Jan 2026
Summary Burney U.S. Factor Rotation ETF initiated a new position in Viatris Inc by purchasing 222,793 shares, bringing its total holdings to 222,793 shares a
Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer
09:05am, Thursday, 08'th Jan 2026
PITTSBURGH, Jan. 8, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) announced today that Lara Ramsburg has been appointed Chief People and Corporate Affairs Officer. As part of Viatris' ongoing tran
Viatris (VTRS) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Tuesday, 06'th Jan 2026
Viatris (VTRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration
09:00am, Tuesday, 06'th Jan 2026
Management to Participate in the 44th Annual J.P. Morgan Healthcare Conference Management to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Viatris Gets FDA Nod for Generic Sandostatin, Shares Regulatory Updates
01:20pm, Friday, 19'th Dec 2025
VTRS scores four regulatory wins in 2025, from FDA approval of a generic Sandostatin LAR to NDA and IND clearances across its pipeline.
Viatris Provides Pipeline Update on Four Regulatory Milestones
06:59am, Thursday, 18'th Dec 2025
Receives U.S. Food and Drug Administration (FDA) Approval for Generic Version of Sandostatin® LAR Depot (Octreotide Acetate for Injectable Suspension) U.S. FDA Accepts New Drug Application for Low Do
Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference
06:59am, Wednesday, 17'th Dec 2025
PITTSBURGH , Dec. 17, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference
